Barclays PLC lifted its position in shares of argenx SE – (NASDAQ:ARGX) by 188.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,630 shares of the company’s stock after buying an additional 14,130 shares during the quarter. Barclays PLC owned about 0.06% of argenx worth $2,465,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Tower Research Capital LLC TRC acquired a new position in argenx in the third quarter valued at $37,000. Marshall Wace LLP bought a new stake in shares of argenx during the 1st quarter valued at about $121,000. Flinton Capital Management LLC bought a new stake in shares of argenx during the 2nd quarter valued at about $156,000. Pacer Advisors Inc. acquired a new stake in argenx during the third quarter worth approximately $128,000. Finally, First Trust Advisors LP acquired a new stake in argenx during the second quarter worth approximately $212,000. Institutional investors own 58.48% of the company’s stock.
ARGX has been the topic of a number of research analyst reports. Wells Fargo & Co began coverage on argenx in a report on Friday, September 27th. They set a “market perform” rating and a $125.00 price target on the stock. SunTrust Banks raised their price target on shares of argenx from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, November 18th. Morgan Stanley lifted their price target on shares of argenx from $143.00 to $173.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. William Blair raised shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. began coverage on shares of argenx in a report on Tuesday, October 22nd. They set an “overweight” rating and a $167.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $158.75.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Read More: What does an outperform rating mean?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.